Clover Biopharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top 18 shareholders own 51.64% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
16.2%	Peng Liang	209,861,821	HK$58.8m	0.03%	no data
12.2%	Hillhouse Investment Management, Ltd.	157,593,429	HK$44.1m	0%	0.05%
5.4%	Chengdu Tianhe Conventional Chinese and Medicine Technology Nurture Co. Ltd	69,999,500	HK$19.6m	0%	no data
4.82%	Super Novel International Limited	62,518,131	HK$17.5m	0%	no data
3.79%	National Council for Social Security Fund	49,213,878	HK$13.8m	0%	no data
2.71%	Lapam Capital	35,152,768	HK$9.8m	0%	0.72%
2.36%	Chengdu Ronghui Datong Equity Investment Fund Management Co., Ltd.	30,660,000	HK$8.6m	0%	no data
2.19%	Xiaodong Wang	28,404,875	HK$8.0m	0.37%	no data
1.6%	Joshua G. Liang	20,734,895	HK$5.8m	0.59%	no data
0.14%	The Core Trust Company Limited	1,870,611	HK$523.8k	0%	no data
0.093%	GF Fund Management Co., Ltd.	1,209,500	HK$338.7k	0%	no data
0.062%	Ralf Leo Clemens	805,944	HK$225.7k	2.2%	no data
0.031%	Jeffrey S. Farrow	404,875	HK$113.3k	34.6%	no data
0.031%	Thomas Edward Leggett	404,875	HK$113.3k	34.6%	no data
0.031%	Xiaobin Wu	404,875	HK$113.3k	34.6%	no data
0.031%	Xiang Liao	404,875	HK$113.3k	34.6%	no data
0.014%	Donna Marie Ambrosino	187,074	HK$52.4k	1.41%	no data
0.00039%	China Universal Asset Management Company Ltd.	5,000	HK$1.4k	0%	no data